Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Endostatin has been widely applied for the clinical treatment of partial primary and
metastatic solid tumors. Endostatin combined with chemotherapy has achieved favorable
progression in the treatment of non-small cell lung cancer (NSCLC). However, the research
about the efficacy of Endostatin on breast cancer has just started. Breast cancer is a
highly-differentiated solid tumor, indicating that it is also an indicator for Endostatin
therapy. Additionally, after chemo- and radiotherapy, the primary nidi of patients with
advanced breast cancer may also lead to rapid development of tumors in other locations. So
Endostatin combined with chemotherapy can also improve the prognosis of patients with
recurrent metastatic breast cancer, but there is rare any report at home and abroad. To
further explore the above research, this study designed a randomized, opened and controlled
clinical study to observe the clinical efficacy of EndostarTM Injection combined with
GP/NP/GX/NX in the treatment of recurrent metastatic breast cancer.